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Introduction
Autism spectrum disorders (ASDs) form a heterogeneous group of
neurodevelopmental disorders defined behaviourally by three core
disturbances: marked deficits in interpersonal social interaction,
disrupted verbal and non-verbal communication, and restricted
repetitive and stereotyped patterns of behaviour and interests 
[1, 2]. The ASD phenotype includes the classical or typical autistic
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Abstract
Autism spectrum disorders (ASDs), which include the prototypic autistic disorder (AD), Asperger’s syndrome (AS) and pervasive devel-
opmental disorders not otherwise specified (PDD-NOS), are complex neurodevelopmental conditions of unknown aetiology. The current
study investigated the metabolites in the methionine cycle, the transsulphuration pathway, folate, vitamin B12 and the C677T polymor-
phism of the MTHFR gene in three groups of children diagnosed with AD (n  15), AS (n  5) and PDD-NOS (n  19) and their age-
and sex-matched controls (n  25). No metabolic disturbances were seen in the AS patients, while in the AD and PDD-NOS groups,
lower plasma levels of methionine (P  0.01 and P  0.03, respectively) and -aminobutyrate were observed (P  0.01 and P  0.001,
respectively). Only in the AD group, plasma cysteine (P  0.02) and total blood glutathione (P  0.02) were found to be reduced.
Although there was a trend towards lower levels of serine, glycine, N, N-dimethylglycine in AD patients, the plasma levels of these
metabolites as well as the levels of homocysteine and cystathionine were not statistically different in any of the ASDs groups. The serum
levels of vitamin B12 and folate were in the normal range. The results of the MTHFR gene analysis showed a normal distribution of the
C677T polymorphism in children with ASDs, but the frequency of the 677T allele was slightly more prevalent in AD patients. Our study
indicates a possible role for the alterations in one carbon metabolism in the pathophysiology of ASDs and provides, for the first time,
preliminary evidence for metabolic and genetic differences between clinical subtypes of ASDs.
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disorder (AD), Asperger syndrome (AS) characterized by no gener-
al delay in language or cognitive development and pervasive devel-
opmental disorders not otherwise specified (PDD-NOS), which is a
milder condition that includes some, but not all, of the symptoms
associated with classic autism. Once considered a rare clinical enti-
ty, autism is now considered common, with the most recent preva-
lence estimate around 1 in 150 [3, 4]. In the scientific literature,
there is varying support for a wide spectrum of hypotheses regarding
the causes of autism: from studies showing that genes play a
greater role in the risk for autism than in any other common neu-
ropsychiatric disorder [5] to studies implicating disruptive environ-
mental factors during neurodevelopment in genetically susceptible
individuals [6]. Nevertheless, it is becoming increasingly obvious
that a single cause or unifying theory is unlikely to account for what
is now better referred to as ‘the autisms’ [7, 8]. What is both
intriguing and frustrating for researchers investigating the patho-
physiological basis of this neurodevelopmental group of disorders
is that no specific biomarker for autism has been identified yet in
order to improve the reliability of behavioural diagnosis.
While inborn errors of metabolism can probably account for less
than 5% of autistic individuals [9], it has recently been suggested
that disturbances in one carbon metabolism (Fig. 1) are a frequently
encountered feature of autism [10–19]. The metabolic distur-
bances have been suggested to contribute to the increased oxidative
stress and impaired redox homeostasis that have been documented
in autism [20], but also to a diminished capacity for methylation,
with consequences on gene expression, neurotransmitter synthesis
and, potentially, on neuronal synchronization [16].
The current study further broadens the metabolic and genetic
dataset on the group of ASD patients by assessing one carbon
metabolites in plasma, folate and vitamin B12 in serum, and the
C677T polymorphism in the MTHFR gene in three groups of chil-
dren diagnosed with one of the ASD clinical subtypes (i.e. AD,
PDD-NOS and AS) as compared to healthy age- and sex-matched
controls. Our data suggest that the severity of these impairments
vary across the clinical spectrum.
Materials and methods
Participants
The subjects enrolled in this study were 39 children with ASD. Each patient
was examined by an experienced child neuropsychiatrist and assigned a
diagnosis of AD (n  15; 13 males, 2 females; mean age: 5.10  0.45
years), PDD-NOS (n  19; 13 males, 6 females; mean age: 8.83  0.84
years) or AS (n  5; 5 males; mean age: 9.23  1.82 years) based on the
criteria defined in the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IVR) [2]. Patients with childhood disinte-
grative disorder or rare syndromes displaying autistic features were
excluded from participation. Patients in each of the three ASDs subgroups
were matched by age and sex with healthy children from a pool of 25 indi-
viduals, as follows: 13 controls for the AD group, 22 controls for the PDD-
NOS group and 8 controls for the AS group (see Table 1). For the genetic
analysis, additional subjects were recruited for genotyping for the control
group for a total of 80 apparently healthy subjects. All participants in this
study were Caucasians of Romanian origin. None of the children included
in this study had taken vitamin supplements (containing folic acid, vitamin
B12 or vitamin B6) in the last 6 months. Comparison subjects were drawn
from the same geographical area as our patient groups, aiming to recover
the same demographics of the region from where the patients were recruited.
All controls were somatically and behaviourally healthy, had no past or
present history of psychiatric disorder and none of them had ever taken
medications for psychiatric conditions. Informed consent was obtained
and the research protocol was in agreement with the Declaration of
Helsinki of the World Medical Association.
Blood samples
Blood specimens were obtained after overnight fast. Samples (~6 ml in
total) were withdrawn from a cubital vein into blood tubes (with heparin,
EDTA or anticoagulant gel) and immediately stored on ice at 4C. Plasma
(for measuring metabolites) and serum (for measuring vitamins) were sep-
arated by centrifugation at 3000 rpm for 10 min and stored at 20C until
analysis. Samples of whole blood were also stored at 20C for measuring
total blood glutathione and isolating genomic DNA.
Plasma metabolites
Total homocysteine, methionine, total cysteine, cystathionine, serine,
glycine, -aminobutyrate, N-methylglycine and N, N-dimethylglycine were
determined in plasma by stable isotope dilution capillary gas chromatog-
raphy/mass spectrometry (GS-MS), as previously described by Stabler 
et al. [21, 22].
Serum vitamin B12 and folate
Serum B12 and folate concentrations were measured using a Roche Elecsys
2010 immunoassay analyser by an electrochemiluminiscence immunoas-
say (ECLIA) using the Elecsys Vitamin B12 reagent kit and the Elecsys Folate
reagent kit (Roche Diagnostics Gmbh, Mannheim, Germany). The assays
were performed according to the supplier’s recommendation.
Whole blood total glutathione
Total blood glutathione (tGSH) was measured in whole blood by isocratic
RP-HPLC with precolumn derivatization and fluorimetric detection using
the specific Chromsystems kit (Instruments and Chemical Gmbh,
München, Germany). The assay was performed according to the supplier’s
recommendation.
Genetic analysis
Genomic DNA was isolated from whole peripheral blood using the QIAamp
DNA Blood Mini Kit (Qiagen, Hilden, Germany) and was stored at 20C until
further analysis. The genetic polymorphism was determined by using the
LightCycler Real-Time PCR technology based on fluorescence resonance energy
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transfer. MTHFR C677T polymorphism analysis was performed according to
the method described by Aslanidis et al. [23], using the LightCyclerTM high-
speed thermal cycler (Hoffmann-LaRoche, Basel, Swizerland) and the
LightCyclerTM DNA Master HybProbe kit (Roche Molecular Biochemicals,
Mannheim, Germany). Melting curve analysis allowed identification of the
MTHFR 677 polymorphism according to the following melting point tempera-
tures: 63.1C for the C allele and 55.2C for the T allele.
Statistical analysis
The data are presented as means  standard error of the mean (S.E.M.).
The normal distribution of continuous data was checked using the
Kolmogorov-Smirnov test. For normally distributed variables, Student’s 
t-test was used for comparisons between the three ASD groups and their
age- and sex-matched controls. When normality was not present and equal
variance could not be assumed, the Mann–Whitney Rank-Sum Test was
applied. Additionally, the effect size (Cohen’s d based on sample size) for
variables with a significant group mean difference was computed.
Spearman’s rho test was used to evaluate the correlation between different
metabolites. For the polymorphism under study, genotypic and allelic fre-
quencies were calculated. The distribution of genotypes in all groups was
tested for deviation from the Hardy–Weinberg equilibrium. The Pearson’s
chi-square (2) test and Fisher’s exact test were applied to assess differ-
ences in the genotype and allelic (respectively) distribution between
groups of patients and controls. A P-value of less than 0.05 was consid-
ered statistically significant. The SPSS software was used for performing
the analysis.
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Fig. 1 Overview of the one carbon metabolism pathway. Abbreviations: S-adenosylhomocysteine (AdoHcy); S-adenosylmethionine (AdoMet); betaine
homocysteine methyltransferase (BHMT); cystathionine 	-synthase (CBS); cystathionine 
-lyase (CHT); dihydrofolate (DHF); dimethylglycine dehydro-
genase (DMGDH); methionine synthase (MS), methylenetetrahydrofolate reductase (MTHFR); tetrahydrofolate (THF).




The results from metabolite measurements in plasma and serum are
listed in Table 1 and graphically represented in Fig. 2. In both the AD
and PDD-NOS groups plasma levels of methionine (20.69  1.87 M
versus 27.49  2.01 M, P  0.01, Cohen’s d  0.91, and 23.62 
1.09 M versus 27.51  1.27 M, P  0.03, Cohen’s d  0.69,
respectively) and -aminobutyric acid (11.14  1.17 M versus
15.73  1.37 M, P  0.01 and 10.73  0.83 M versus 14.62 
0.74 M, P  0.001, respectively) were lower than in their age-
and sex-matched controls, whereas plasma total homocysteine
was in the normal range. It is worth noting that the decrease in
methionine levels observed in AD was more severe than in PDD-
NOS patients (~25% decrease versus ~14% decrease). Only in the
AD group, plasma cysteine levels (181.06  6.42 M versus
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(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Folate (ng/ml)** 10.45  1.49 8.13  0.68 0.17 7.98  0.75 8.63  0.68 0.53 13.51  2.06 8.17  0.91 0.06
Table 1 Characteristics of groups and biochemical results in patients with ASD and control subjects
Data are presented as mean  standard error of the mean (S.E.M.);
*plasma, # whole blood, ** serum.
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Fig. 2 Levels of methionine, homocysteine, cysteine, total glutathione and -aminobutyrate in children with AD (A) and PDD-NOS (B) compared to controls.
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204.76  7.16 M, P  0.02; Cohen’s d  0.91) and total blood
glutathione (161.16  10.68 M versus 242.67  32.94 M, 
P  0.02; Cohen’s d  0.89) were found to be lower. In contrast,
the plasma levels of other amino acids, such as cystathionine, 
serine, glycine, N-methylglycine and N, N-dimethylglycine did not
differ significantly from those of normal controls in any of the ASD
groups, although there was a trend towards lower levels of serine,
glycine and N, N-dimethylglycine in the AD patients (Table 1). The
levels of serum vitamin B12 were in the normal range of values in
all ASDs groups; only 3 children with AD had levels below 
250 pg/ml, but all subjects with a PDD-NOS diagnosis had levels
above this suboptimal value. Serum folate levels were also in the
normal range, except for mildly higher levels in AS which reached 
a borderline statistical significance (13.51  2.06 ng/ml versus
8.17  0.91 ng/ml, P  0.06). However, in the context of the
small group size, this apparent difference in B12 levels needs to be
treated with caution.
We also examined the correlations between metabolite levels in
the three groups of ASDs patients. In AD patients we found a pos-
itive correlation between tHcy levels and cysteine (rho  0.54, 
P  0.04), cystathionine (rho  0.56, P  0.03) and total blood
glutathione (rho  0.48, P  0.08); methionine was negatively
correlated with cysteine, but statistical significance was not
reached (rho  0.30, P  0.27). In the AD group, we also
observed a negative correlation between levels of N, N-dimethyl-
glycine and cysteine (rho  0.55, P  0.03) and a positive cor-
relation between N-methylglycine and serum folate (rho  0.44, 
P  0.09). Only in the PDD-NOS group a strong positive correla-
tion was noticed between methionine and -aminobutyric acid
(rho  0.66, P  0.002).
Genotyping results
The MTHFR C677T genotype data, summarized in Table 2, were
obtained from 80 healthy controls and 39 patients with an ASD
diagnosis (AD: n  15; PDD-NOS: n  19; AS: n  5). The geno-
type distributions were all within the Hardy–Weinberg equilibrium.
Although, at the moment, there are no reliable data on the MTHFR
C677T polymorphic distribution in the general Romanian popula-
tion, the frequency observed in our control group (CC, 57.5%; CT,
35.0%; TT, 7.5%; C/T, 0.75/0.25) is similar to that reported for
other Central European populations [24]. The polymorphic T allele
frequency of MTHFR was 0.31 in the ASD group (0.40 in AD, 0.21
in PDD-NOS and 0.20 in AS) as compared with 0.25 in the healthy
controls. There was no statistical difference in the distribution of
the genotypes (2  0.30, P  0.85) or alleles (2  0.27, P 
0.60) between ASD patients overall and controls. The genotype
and allele frequency was also similar in the subgroup of patients
with PDD-NOS when compared with subjects in the general pop-
ulation (2  0.12, P  0.73 and 2  26, P  0.61, respectively).
However, the T allele was slightly more prevalent in the AD group
than in controls (C/T, 0.40 versus C/T, 0.25), although the differ-
ence reached only borderline statistical significance (2  0.85, 
P  0.09).
Discussion
One of the current obstacles in autism research is the clinical het-
erogeneity of the disorder, which is worsened by the absence of
any reliable biological marker. The prototypical AD is diagnosed on
the basis of the triad of behavioural impairments (i.e. social inter-
action, communication and restrained interests) before 3 years of
age. Conversely, patients with the AS clinical subtype display
apparently normal language and cognitive development, while the
PDD-NOS category or atypical autism comprises cases that have
many, but not all, of the defining features of AD or AS. Often, the
severity or extent of the symptomatology in PDD-NOS patients is
less severe, or the presentation is otherwise atypical, with a level of
functioning that scores between that of the children with AD and
that of the children with AS [25]. The degree to which ASD condi-
tions, which share the common feature of dysfunctional reciprocal
© 2008 The Authors
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AD Controls AD P PDD-NOS
Controls
PDD-NOS
P AS Controls AS P
Number of subjects 15 80 19 80 5 80
MTHFR C677T
CC 6 (40.0%) 46 (57.5%) 0.23 12 46 (57.5%) 0.88 3 (60%) 46 (57.5%) 0.81
CT 6 (40.0%) 28 (35.0%) 6 28 (35.0%) 2 (40%) 28 (35.0%)
TT 3 (20.0%) 6 (7.5%) 1 6 (7.5%) 0 (0%) 6 (7.5%)
C/T 0.60/0.40 0.75/0.25 0.09 0.79/0.21 0.75/0.25 0.60 0.80/0.20 0.75/0.25 0.72
Table 2 The MTHFR C677T polymorphism in patients with ASD and control subjects
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social interaction, are independent developmental disorders is not
known. Nonetheless, it is becoming increasingly recognized that no
single explanation accounts for all autism(s) and multiple factors
(genetic, epigenetic and environmental) are involved in shaping the
phenotype [6–8, 26].
During the last two decades, several studies have indicated dis-
ruptions in one carbon metabolism (Fig. 1) accompanying differ-
ent neurological and psychiatric disorders [27, 28]. The implica-
tions for these alterations in the methionine cycle and/or the
transsulphuration pathway in neuropsychiatric conditions can be
pathogenetically translated to disruptions in the methylation status,
alterations in gene expression and a decreased ability to counteract
neuronal oxidative stress. Recently, autism has also been linked to
such metabolic perturbations, as reported in studies investigating
plasma metabolites [10–13, 18, 19] or in immune cells [17] in
ASD patients.
In the present study, we investigated one carbon metabolism
in children with ASD, this being the first study with an emphasis
on possible differences in the metabolic profiles between the
clinical subtypes (i.e. AD, PDD-NOS and AS). Our results con-
firmed the presence of disturbances in these metabolic path-
ways, except for patients with the AS clinical subtype, who
exhibited normal levels of metabolites. However, we found 
differences in the severity of the metabolite profiles across the
spectrum of autistic disorders, with AD patients exhibiting dis-
turbances in both the methionine cycle and the transsulphura-
tion pathway concomitant with a slightly more prevalent T allele
frequency for the MTHFR C677T polymorphism, while patients
with the less severe form of the disease (i.e. PDD-NOS) present-
ing only with disturbances in the methionine cycle. In addition,
since the levels of both folate and vitamin B12 were within the
normal range, we excluded vitamin deficiencies as a cause for
these impairments. Therefore, more sensitive vitamin deficien-
cies markers are needed in future studies, taking also into con-
sideration the fact that extracellular vitamin levels (i.e. in the
serum) do not necessarily extrapolate to intracellular vitamin
status. From these metabolic and genetic profiles it can be con-
cluded that no single cause can be incriminated, rather, multifac-
torial interactions between environmental, including dietary, and
genetic factors are likely to be culpable.
In the AD group and to a lesser extent in the PDD-NOS group,
we found low levels of plasma methionine despite the fact that all
children were on an unrestricted diet. Low methionine has been
consistently reported in autism by other groups [10, 11, 13], and
it could be the result of low dietary intake. In addition, in both AD
and PDD-NOS, we observed low levels of -aminobutyrate, a
metabolite of -ketobutyrate. This is consistent with a low methio-
nine input with consequent low flux through the transsulphuration
pathway. Repetitive behaviours and insistence on sameness can
have a deleterious impact on the patient’s ability to feed effectively
and receive adequate nutrition. Children with AD and PDD-NOS
have been reported to exhibit atypical feeding behaviour, with a
highly restricted range of taste- and/or texture-based food choices
[29]. Arnold et al. showed that children with autism on an unre-
stricted diet are significantly more likely to have deficiencies in
essential amino acids, including methionine, which is consistent
with poor protein nutrition [30]. Nonetheless, children with ASD
from a recent study had high protein content in their diet, although
they also had a high rate of reported gastrointestinal symptoms
without an apparent medical cause [31].
In children with AD, the trend towards lower serine, glycine
and N, N-dimethylglycine that accompanies lower methionine sug-
gests that the remethylation pathway is perturbed. The observa-
tion that the thermolabile 677T allele of the MTHFR gene, which is
associated with a decrease in enzymatic activity to 50–60% in
homozygotes [32], is slightly more prevalent in the typical autism
group, suggests that this polymorphism might contribute to the
aforementioned metabolic disturbance. Two other studies indicated
that the MTHFR C677T polymorphism is associated to a greater
[15] or lesser degree [11] with ASD. Because of the small patient
sample, we could not examine the influence of the MTHFR gene
polymorphism on the metabolic profile. Future studies should 
further investigate the relative contribution of the less active 
variant of the MTHFR gene across the autism spectrum. The
remethylation pathway, catalysed by 5-methyltetrahydrofo-
late–homocysteine S-methyltransferase or methionine synthase,
requires vitamin B12 and folate (methyltetrahydrofolate) as coen-
zyme and as cosubstrate (methyl donor), respectively. The levels
of serum vitamin B12 and folate were normal in children with AD,
and apparently vitamin deficiencies are not the cause for the alter-
ations in the methionine cycle. This does not necessarily rule out
a cerebral deficiency of folate, which has been described in autis-
tic patients [14] or an intracellular deficiency, since the RFC C80A
variant of reduced folate carrier has been showed to be more fre-
quent in autistics [11]. Moreover, preliminary data showed that the
19 bp-deletion polymorphism in dihydrofolate reductase (DHFR)
is associated with autism, despite normal folate, vitamin B12 and
homocysteine levels, and it seems likely that this polymorphism
interacts with the MTHFR and RFC single nucleotide polymor-
phisms to further modify the risk [18]. In addition, other studies
have indicated a high prevalence of iron deficiency in AD and AS
and that this is associated with falsely increased to normal folic
acid levels [33]. In our study we did not evaluate the levels of 
S-adenosylmethionine (AdoMet) and S-adenosylhomocysteine
(AdoHcy), but the available data in the literature consistently sug-
gest an impaired transmethylation capacity in autistic patients (i.e.
low AdoMet/AdoHcy ratio) [10, 11].
Interestingly, we did not observe higher levels of plasma
homocysteine in children with AD, in contrast to our previous
study in which hyperhomocysteinemia was present in children
with ASD, but this was accompanied by suboptimal levels of vita-
min B12 [12]. Suh et al. recently demonstrated high intracellular
homocysteine in leukocytes from autistic children, despite normal
plasma levels [17]. It remains to be explored how much the blood
metabolic profiles in autism reflect the actual intracellular meta-
bolic dynamics, especially since there have been recent reports
showing altered transport of amino acids across the cellular mem-
brane of cultured fibroblasts from autistic patients [34].
© 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
4236
What is particularly novel about our results is the fact that only
children with typical autism (i.e. AD), but not PDD-NOS, have
impairments in the transsulphuration pathway. More specifically,
only children with AD had lower levels of plasma cysteine and total
blood glutathione. Interestingly, the levels of cystathionine were
within the normal range. Low levels of cysteine and glutathione
accompanied by higher levels of cystathionine have also been
described in the ASD group investigated by James et al. [11], and
it could indicate a defect at the level of cystathionine gamma-lyase
(CTH), a pyridoxal 5-phosphate dependent enzyme that converts
cystathionine to cysteine in the transsulphuration pathway.
Another recent investigation reported that leukocytes from autistic
children exhibit decreased intracellular cysteine and total glu-
tathione, and unlike the findings in plasma, show a significant
(80%) increase in intracellular homocysteine [17]. While in several
studies children with ASD exhibited higher levels of vitamin B6
than the control subjects [35–37], the activity of pyridoxal kinase
and the levels of pyridoxal 5-phosphate had been measured and
found to be generally much lower than levels in control subjects
[37]. It has also been suggested that the reduced flux through
transsulphuration in autism, with a consequent diminished glu-
tathione pool, could also be due to the high levels of androgens
described in these patients [13, 38] since testosterone modulates
the activity of CBS [39, 40]. The low levels of cysteine and glu-
tathione, the decrease in the ratio of reduced to oxidized glu-
tathione in plasma and the decreased ability to form sulphated
metabolites in autistic patients [41] suggest that antioxidant
defences are compromised in these patients [20]. Glutathione is
also very important to heavy metal detoxification [42], and the
variations in glutathione abnormalities across the ASD suggests
the possibility that it might be functionally significant since it was
shown that mercury-associated urinary porphyrin levels increase
with increasing severity of ASDs [43–45]. Finally, it is important to
discuss the limitations of our study. First, the number of subjects
was relatively small and, unfortunately, no quantitative standard-
ized scale for autism has been applied. Second, being a retrospec-
tive study it does not provide information about the dynamics of
metabolite changes associated with different stages of develop-
ment and/or in response to different dietary supplements (i.e.
betaine, folic acid, vitamin B6, vitamin B12). By the same token, an
interesting aspect of this study is that it represents the first inves-
tigation of one carbon metabolism in children with different sub-
types of ASD who are free of vitamin supplements.
In conclusion, our results indicate disturbances in both the
methionine cycle and the transsulphuration pathway in children
with AD, which are most likely multifactorial in origin.
Interestingly, children with milder clinical forms of ASD display
milder metabolic perturbations. To date, only a few studies have
specifically reported biological correlates of different clinical sub-
types in the autistic spectrum (e.g. [46, 47]). The methylation
deficit resulting from an altered methionine cycle supports the
previously suggested contribution of epigenetic mechanisms to
the pathogenesis of autism [26]. Aside from this ‘metabolic repro-
gramming’ of gene expression, dysfunctionalities in the synthesis
of neurotransmitters and phospholipids would also result [28,
48]. Genomic imprinting is the classic example of regulation of
gene expression via epigenetic modifications that leads to parent
of origin-specific gene expression. From this perspective, the dis-
turbances in the methionine cycle and the ensuing methylation
deficit in AD patients support the imprinting hypothesis for the
development of autism, which emphasizes the imbalances in brain
development due to enhanced effects of paternally expressed
imprinted genes [49]. In addition, disturbances in the methionine
cycle have been hypothesized to contribute to alterations in neu-
ronal synchronization in autism [16, 50]. On the other hand, the
low levels of glutathione, resulting from the decreased flow
through transsulphuration in AD, is indicative of an imbalance in
the redox homeostasis, and links oxidative stress with membrane
lipid abnormalities, inflammation and aberrant immune response
that have been observed in autism [20].
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12. Paşca SP, Nemes B, Vlase L, et al. High
levels of homocysteine and low serum
paraoxonase 1 arylesterase activity in chil-
dren with autism. Life Sci. 2006; 78:
2244–8.
13. Geier DA, Geier MR. A clinical and labora-
tory evaluation of methionine cycle-
transsulfuration and androgen pathway
markers in children with autistic disorders.
Horm Res. 2006; 66: 182–8.
14. Moretti P, Peters SU, Del Gaudio D, et al.
Brief report: autistic symptoms, develop-
mental regression, mental retardation,
epilepsy, and dyskinesias in CNS folate
deficiency. J Autism Dev Disord. 2008; 38:
1170–7.
15. Boris M, Goldblatt A, Galanko J, 
et al. Association of MTHFR gene variants
with autism. J Am Phys Surg. 2004; 9:
106–8.
16. Deth R, Muratore C, Benzecry J, et al.
How environmental and genetic factors
combine to cause autism: A redox/ 
methylation hypothesis. Neurotoxicology.
2008; 29: 190–201.
17. Suh J, Walsh W, McGinnis W, et al.
Altered sulfur amino acid metabolism in
immune cells of children diagnosed with
autism. Am J Biochem Biotech. 2008; 4:
105–13.
18. Adams M, Lucock M, Stuart J, et al.
Preliminary evidence for involvement of
the folate gene polymorphism 19bp dele-
tion-DHFR in occurrence of autism.
Neurosci Lett. 2007; 422: 24–9.
19. Geier DA, Kern JK, Garver CR, et al. A
prospective study of transsulfuration bio-
markers in autistic disorders. Neurochem
Res. 2009; 34: 394.
20. Chauhan A, Chauhan V. Oxidative stress in
autism. Pathophysiology. 2006; 13:
171–81.
21. Stabler SP, Lindenbaum J, Savage DG, 
et al. Elevation of serum cystathionine lev-
els in patients with cobalamin and folate
deficiency. Blood. 1993; 81: 3404–13.
22. Stabler SP, Marcell PD, Podell ER, et al.
Elevation of total homocysteine in the
serum of patients with cobalamin or folate
deficiency detected by capillary gas chro-
matography-mass spectrometry. J Clin
Invest. 1988; 81: 466–74.
23. Aslanidis C, Nauck M, Schmitz G. High-
speed prothrombin G–A 20210 and
methylenetetrahydrofolate reductase
C–T 677 mutation detection using real-
time fluorescence PCR and melting curves.
Biotechniques. 1999; 27: 234–6, 8.
24. Moore LE, Hung R, Karami S, et al. Folate
metabolism genes, vegetable intake and
renal cancer risk in central Europe. Int J
Cancer. 2008; 122: 1710–5.
25. Walker DR, Thompson A, Zwaigenbaum
L, et al. Specifying PDD-NOS: a compari-
son of PDD-NOS, Asperger syndrome, 
and autism. J Am Acad Child Adolesc
Psychiatry. 2004; 43: 172–80.
26. Schanen NC. Epigenetics of autism spec-
trum disorders. Hum Mol Genet. 2006; 2:
R138–50.
27. Sugden C. One-carbon metabolism in psy-
chiatric illness. Nutr Res Rev. 2006; 19:
117–36.
28. Muskiet FA, Kemperman RF. Folate and
long-chain polyunsaturated fatty acids in
psychiatric disease. J Nutr Biochem. 2006;
17: 717–27.
29. Ahearn WH, Castine T, Nault K, et al. An
assessment of food acceptance in children
with autism or pervasive developmental
disorder-not otherwise specified. J Autism
Dev Disord. 2001; 31: 505–11.
30. Arnold GL, Hyman SL, Mooney RA, et al.
Plasma amino acids profiles in children
with autism: potential risk of nutritional
deficiencies. J Autism Dev Disord. 2003;
33: 449–54.
31. Levy SE, Souders MC, Ittenbach RF, 
et al. Relationship of dietary intake to 
gastrointestinal symptoms in children 
with autistic spectrum disorders. Biol
Psychiatry. 2007; 61: 492–7.
32. Rozen R. Genetic predisposition to hyper-
homocysteinemia: deficiency of methyl-
enetetrahydrofolate reductase (MTHFR).
Thromb Haemost. 1997; 78: 523–6.
33. Latif A, Heinz P, Cook R. Iron deficiency in
autism and Asperger syndrome. Autism.
2002; 6: 103–14.
34. Fernell E, Karagiannakis A, Edman G, 
et al. Aberrant amino acid transport in
fibroblasts from children with autism.
Neurosci Lett. 2007; 418: 82–6.
35. Siva Sankar DV. Plasma levels of folates,
riboflavin, vitamin B6, and ascorbate in
severely disturbed children. J Autism Dev
Disord. 1979; 9: 73–82.
36. Adams JB, George F, Audhya T.
Abnormally high plasma levels of vitamin
B6 in children with autism not taking sup-
plements compared to controls not taking
supplements. J Altern Complement Med.
2006; 12: 59–63.
37. Adams JB, Holloway C. Pilot study of a
moderate dose multivitamin/mineral sup-
plement for children with autistic spectrum
disorder. J Altern Complement Med. 2004;
10: 1033–9.
38. Geier DA, Geier MR. A prospective
assessment of androgen levels in patients
with autistic spectrum disorders: biochem-
ical underpinnings and suggested thera-
pies. Neuro Endocrinol Lett. 2007; 28:
565–73.
39. Prudova A, Albin M, Bauman Z, et al.
Testosterone regulation of homocysteine
metabolism modulates redox status in
human prostate cancer cells. Antioxid
Redox Signal. 2007; 9: 1875–81.
40. Vitvitsky V, Prudova A, Stabler S, et al.
Testosterone regulation of renal cystathio-
nine beta-synthase: implications for sex-
dependent differences in plasma homocys-
teine levels. Am J Physiol Renal Physiol.
2007; 293: F594–600.
41. Alberti A, Pirrone P, Elia M, et al.
Sulphation deficit in “low-functioning”
autistic children: a pilot study. Biol
Psychiatry. 1999; 46: 420–4.
42. Clarkson TW, Nordberg GF, Sager PR.
Reproductive and developmental toxicity
of metals. Scand J Work Environ Health.
1985; 11: 145–54.
43. Nataf R, Skorupka C, Amet L, et al.
Porphyrinuria in childhood autistic 
disorder: implications for environmental
toxicity. Toxicol Appl Pharmacol. 2006;
214: 99–108.
44. Geier DA, Geier MR. A prospective study
of mercury toxicity biomarkers in autistic
spectrum disorders. J Toxicol Environ
Health A. 2007; 70: 1723–30.
45. Geier DA, Geier MR. A prospective
assessment of porphyrins in autistic disor-
ders: a potential marker for heavy metal
exposure. Neurotox Res. 2006; 10: 57–64.
46. Boger-Megiddo I, Shaw DW, Friedman
SD, et al. Corpus callosum morphometrics
in young children with autism spectrum
4238 © 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
disorder. J Autism Dev Disord. 2006; 36:
733–9.
47. Connolly AM, Chez M, Streif EM, 
et al. Brain-derived neurotrophic factor
and autoantibodies to neural antigens in
sera of children with autistic spectrum 
disorders, Landau-Kleffner syndrome, and
epilepsy. Biol Psychiatry. 2006; 59:
354–63.
48. Van den Veyver IB. Genetic effects of
methylation diets. Annu Rev Nutr. 2002;
22: 255–82.
49. Badcock C, Crespi B. Imbalanced 
genomic imprinting in brain development:
an evolutionary basis for the aetiology 
of autism. J Evol Biol. 2006; 19: 
1007–32.
50. Uhlhaas PJ, Singer W. What do 
disturbances in neural synchrony tell us
about autism? Biol Psychiatry. 2007; 62:
190–1.
